CDC expedites release of more doses of infant RSV drug from Sanofi, AstraZeneca amid shortage
Publishing timestamp: 2023-11-17 08:44:39
Summary
The CDC has expedited the release of over 77,000 additional doses of a new drug called Beyfortus, a monoclonal antibody from Sanofi and AstraZeneca, to protect infants from respiratory syncytial virus (RSV). This comes as RSV cases rise in some parts of the country ahead of the holiday season. The drug is one of two available treatments in the U.S. that can protect infants from the virus, which is a leading cause of hospitalization among babies nationwide. The CDC's move aims to increase availability of the drug amid an ongoing shortage and high demand. The additional doses will be distributed to physicians and hospitals through commercial channels and the Vaccines for Children Program. The CDC and FDA will continue to work with drug manufacturers to ensure availability of additional doses to meet demand.
Sentiment: NEUTRAL
Keywords: astrazeneca plc, biotech and pharmaceuticals, pharmaceuticals, business, sanofi sa, biotechnology, social issues, breaking news, health care industry, business news, united states,